Amylyx Pharmaceuticals (AMLX) Revenue (2021 - 2024)

Amylyx Pharmaceuticals has reported Revenue for 4 years, with the latest figure at -$636000.0 in Q4 2024.

• On a quarterly basis, Revenue fell 100.59% year-over-year to -$636000.0 in Q4 2024; TTM through Sep 2025 was -$636000.0, a 100.32% decrease from a year earlier, with the FY2024 full-year figure at $87.4 million, down 77.05% from the prior year.
• Revenue was -$636000.0 for Q4 2024 at Amylyx Pharmaceuticals, down from $416000.0 in the prior quarter.
• The five-year high for Revenue was $108.4 million in Q4 2023, with the low at -$636000.0 in Q4 2024.
• Average Revenue over 4 years is $44.8 million, with a median of $21.9 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: Revenue jumped 29666.09% in 2023, then sank 100.59% in 2024.
• Over 4 years, Revenue stood at $285000.0 in 2021, then jumped by 7578.95% to $21.9 million in 2022, then jumped by 395.54% to $108.4 million in 2023, then tumbled by 100.59% to -$636000.0 in 2024.
• The last three Revenue figures came in at -$636000.0 (Q4 2024), $416000.0 (Q3 2024), and $1.0 million (Q2 2024), per Business Quant data.